Elman Scott A, Weinblatt Michael, Merola Joseph F
Departments of Dermatology and Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Semin Cutan Med Surg. 2018 Sep;37(3):173-181. doi: 10.12788/j.sder.2018.045.
Dermatologists are on the front line to identify psoriatic arthritis (PsA) in their patients with psoriasis. PsA is a prevalent and underdiagnosed disease with potential long-term complications and sequelae for patients. Targeted biologics have transformed the landscape of psoriasis and PsA therapy. These medications variably treat clinical manifestations of psoriatic disease: skin psoriasis, peripheral and axial arthritis, enthesitis, and nail disease. With many new medications either on the market or currently being evaluated by the Food and Drug Administration, the purpose of this article is to review PsA for the dermatologist, to identify the current therapies that are available, and to help select which patients may benefit from these medications. Overall, it is important to decide therapy for patients based on the active domains of their disease, their comorbidities, and the safety profiles of these medications, as well as patient preference for route of administration, frequency, and tolerability.
皮肤科医生处于识别银屑病患者中银屑病关节炎（PsA）的前沿。PsA是一种常见但诊断不足的疾病，对患者有潜在的长期并发症和后遗症。靶向生物制剂改变了银屑病和PsA的治疗格局。这些药物能不同程度地治疗银屑病相关的临床表现：皮肤银屑病、外周和中轴关节炎、附着点炎和指甲病变。随着许多新药上市或正在接受美国食品药品监督管理局的评估，本文旨在为皮肤科医生综述PsA，确定现有的治疗方法，并帮助选择哪些患者可能从这些药物中获益。总体而言，根据患者疾病的活动领域、合并症、这些药物的安全性概况以及患者对给药途径、频率和耐受性的偏好来为患者决定治疗方案非常重要。
